Tissue Sectioning Market (2026 - 2033)

Tissue Sectioning Market Summary

The global tissue sectioning market size was valued at USD 717.9 million in 2025 and is projected to grow from USD 755.3 million in 2026 to USD 1,145.3 million by 2033, at a CAGR of 6.1% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 41.0% in 2025. The market growth is driven by the rising number of cancer cases and biopsies that must be sectioned for diagnosis, the growing number of IHC, molecular, and spatial biology tests performed on each tissue block, and shortages of histotechnologists and pathologists that are pushing laboratories toward automated microtomes and cryostats.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

To learn more about this report, Download Free Sample Report

Market Dynamics

The tissue sectioning market is growing steadily, as every tissue biopsy and surgical specimen examined under the microscope must first be cut into thin sections on a microtome or cryostat. The volume of such specimens is rising with the global cancer burden. According to Global Cancer Statistics 2026, published by the American Cancer Society and the International Agency for Research on Cancer in July 2026, nearly 21 million people were diagnosed with cancer and 9.8 million died from the disease worldwide in 2024, and new cases are projected to reach 34 million by 2050. Each cancer diagnosis typically generates several tissue blocks and many sections for H&E, special stains, and biomarker testing.

Market Concentration & Characteristics

The degree of innovation in the tissue sectioning market is moderate to high, driven by motorized and robotic microtomy, ergonomic cryostats, and sectioning workflows designed for digital pathology. For instance, in April 2024, Clarapath formed a strategic collaboration with Mayo Clinic to advance SectionStar, an automated tissue sectioning, transfer, and quality control system that combines robotics, computational AI, and histopathology workflows, and Mayo Clinic's chair of anatomic pathology joined Clarapath's Board of Directors.

The tissue sectioning market is experiencing moderate M&A activity as leading histology suppliers broaden their workflow portfolios. For instance, in July 2026, Leica Biosystems, a Danaher company, signed a definitive agreement to acquire StatLab Medical Products, a developer and manufacturer of anatomic pathology products that owns the microtome maker Diapath, from Linden Capital Partners and Audax Private Equity, with closing expected by the end of 2026.

“We look forward to welcoming this talented team to Leica Biosystems.”

- Gustavo Perez Fernandez, Group Executive, Danaher Diagnostics, and President, Leica Biosystems

To learn more about this report, Download Free Sample Report

Regulations have a moderate impact on the tissue sectioning market. In the U.S., microtomes, cryostats, and ultramicrotomes are regulated under 21 CFR 864.3010 as Class I devices that are exempt from premarket notification, which lowers the barriers to launching new instruments. In Europe, instruments intended for diagnostic use must carry CE marking under the In Vitro Diagnostic Regulation (IVDR), and laboratories accredited to ISO 15189 must document the validation and maintenance of sectioning equipment.

The tissue sectioning market is witnessing product expansion as companies introduce new instruments into new geographies. For instance, in September 2025, StatLab launched Diapath histology instruments in the U.S., including the Galileo Series 2 precision microtome with the PRO System for higher throughput, at the National Society for Histotechnology Annual Convention.

“When we acquired Diapath, our vision was clear: to expand access to the most innovative histology instrumentation worldwide.”

- Dae Hong, CEO, StatLab

The tissue sectioning market is witnessing regional expansion as companies shift manufacturing closer to growing markets. For instance, according to PHC Holdings' Integrated Report 2026, Epredia moved its pathology production from the UK to Indonesia and expanded its pathology facility in China to strengthen supply in Asia Pacific.

Analyst Perspective

The tissue sectioning market is expected to witness steady growth, supported by the rising number of cancer cases and biopsies, more IHC, molecular, and spatial biology tests per tissue block, growth in preclinical pathology, and shortages of histotechnologists and pathologists. Instruments remain the largest revenue source, as laboratories need several microtomes and cryostats and replace them every 7 to 10 years, while blades and other consumables provide recurring revenue. Fully automated and robotic sectioning systems continue to gain share as laboratories seek consistent sections for digital pathology and AI-based analysis. Market participants are focusing on automated and robotic microtomy, ergonomic and energy-efficient cryostats, acquisitions, and expansion of distribution and manufacturing networks.

Product Insights

The instruments segment accounted for the largest revenue share of 54.1% in 2025, as hospitals, reference laboratories, and research institutes need several rotary microtomes and cryostats per laboratory and replace them every 7 to 10 years. Among instruments, rotary microtomes held the largest share of 41.3% in 2025, while vibratomes are projected to grow the fastest at a CAGR of 6.5%. Public buyers continue to procure advanced cryostats; for instance, in April 2026, the U.S. Department of Veterans Affairs issued a solicitation for an Epredia HM525 NX UV cryostat for the research service of the Central Arkansas Veterans Health Care System.

The accessories & consumables segment is expected to grow at a CAGR of 5.9% over the forecast period, supported by recurring demand for disposable blades, which accounted for 64.1% of the segment in 2025. Laboratories replace blades many times a day; for instance, low-profile disposable blades from Leica and Feather were listed at USD 200-278 per box of 50 by a U.S. distributor in 2026. The services segment is expected to grow at a CAGR of 6.3%, as pharmaceutical companies and research institutes outsource sectioning and histology to contract laboratories.

Technology Insights

The fully automated segment accounted for the largest revenue share of 48.0% in 2025 and is expected to grow at the fastest CAGR of 6.4% over the forecast period, as high-volume laboratories adopt motorized microtomes and cryostats, such as Leica HistoCore AUTOCUT and Sakura Tissue-Tek AutoSection, to improve section consistency and reduce repetitive strain injuries among histotechnologists.

To learn more about this report, Download Free Sample Report

The semi-automated segment is expected to grow at a CAGR of 6.0% during 2026-2033, as mid-sized laboratories choose instruments with motorized section advance and manual cutting that offer a balance of control and cost. The manual segment is expected to grow at a CAGR of 5.8%, supported by demand from teaching laboratories and small laboratories in emerging markets.

Application Insights

The disease diagnosis segment accounted for the largest revenue share of 59.7% in 2025, driven by high volumes of biopsies and surgical resections that are sectioned in hospital and reference pathology laboratories, as well as intraoperative frozen sections and Mohs surgery performed on cryostats.

The drug discovery & preclinical toxicology segment is projected to grow at the fastest CAGR of 6.5% during 2026-2033, supported by growing outsourcing of histopathology in preclinical studies. For instance, in May 2024, HistoWiz added Good Laboratory Practice (GLP) compliant routine histology, IHC, and pathology consultation services to support customers whose research is moving toward FDA submission. The research segment is expected to grow at a CAGR of 6.5%, supported by neuroscience, spatial biology, and electron microscopy studies.

End Use Insights

The hospitals segment accounted for the largest revenue share of 38.0% in 2025, as hospital pathology departments section most biopsies and surgical specimens and perform frozen sections during surgery.

The pharmaceutical & biotechnology companies and CROs segment is expected to grow at the fastest CAGR of 6.5% over the forecast period, driven by preclinical pathology, biomarker, and spatial biology studies. The diagnostic & pathology laboratories segment is expected to grow at a CAGR of 6.3%, as specialized reference laboratories consolidate histology volumes, and the academic & research institutes segment at a CAGR of 6.4%.

Regional Insights

North America dominated the tissue sectioning market, accounting for the largest revenue share of 41.0% in 2025, supported by high cancer testing volumes, a large number of hospital and reference pathology laboratories, early adoption of automated and robotic sectioning, and the presence of leading companies such as Leica Biosystems, Epredia, StatLab, and Clarapath.

To learn more about this report, Download Free Sample Report

U.S. Tissue Sectioning Market Trends

The U.S. tissue sectioning market is expected to grow over the forecast period, supported by a high and rising number of cancer diagnoses that require tissue sections. According to Cancer Statistics, 2026, published by the American Cancer Society in January 2026, an estimated 2,114,850 new cancer cases and 626,140 cancer deaths are projected in the U.S. in 2026, which is anticipated to propel demand for microtomes, cryostats, and blades in pathology laboratories.

Europe Tissue Sectioning Market Trends

The Europe tissue sectioning market is anticipated to grow significantly over the forecast period, supported by a strong base of pathology laboratories and local manufacturers of sectioning instruments, including Leica Biosystems in Nussloch, MEDITE and SLEE medical in Germany, and Diapath and Histo-Line in Italy. Large cancer screening programs and the adoption of digital pathology are increasing the number of high-quality sections required per case.

The UK tissue sectioning market is expected to grow over the forecast period, supported by stronger distribution of sectioning products to research laboratories. For instance, in September 2025, Leica Biosystems and Scientific Laboratory Supplies (SLS) signed a strategic distribution agreement under which SLS sells Leica Biosystems' life science portfolio for tissue-based research to customers in the UK and Ireland.

The tissue sectioning market in Germany is anticipated to grow significantly over the forecast period, supported by a large cancer burden and an ageing population. According to the 15th edition of "Krebs in Deutschland", published by the Robert Koch Institute in December 2025, about 517,800 people in Germany were newly diagnosed with cancer in 2023, which is anticipated to propel demand for tissue sectioning in pathology laboratories.

Asia Pacific Tissue Sectioning Market Trends

Asia Pacific is expected to grow at the fastest CAGR of 7.4% during the forecast period, supported by expanding hospital and pathology laboratory capacity and a rising cancer burden. In India, a study based on the National Cancer Registry Programme, published in the Indian Journal of Medical and Paediatric Oncology in February 2025, projected about 1.57 million new cancer cases in 2025, up 27.7% from 2015.

China's tissue sectioning market is expected to grow over the forecast period, supported by the country's large number of cancer cases and growing domestic production of microtomes and cryostats. According to the National Cancer Center of China, published in the Journal of the National Cancer Center in February 2024, China recorded about 4.82 million new cancer cases and 2.57 million cancer deaths in 2022, which is anticipated to propel demand for histopathology and tissue sectioning.

The Japan tissue sectioning market is expected to grow steadily, supported by an ageing population and the presence of domestic suppliers such as Sakura Finetek. According to the National Cancer Center Japan, about 1,023,100 new cancer cases and 395,500 cancer deaths were projected in Japan in 2025, with colorectal, lung, and stomach cancers the most common.

Latin America Tissue Sectioning Market Trends

The Latin America tissue sectioning market is expected to grow steadily over the forecast period, supported by rising cancer incidence in Brazil. In February 2026, the Brazilian National Cancer Institute (INCA) estimated about 781,000 new cancer cases per year in Brazil for 2026-2028, or about 518,000 excluding non-melanoma skin cancer, which is anticipated to propel demand for histopathology services and sectioning products.

MEA Tissue Sectioning Market Trends

The Middle East & Africa tissue sectioning market is growing steadily, supported by investment in advanced pathology services in Gulf countries. For instance, in November 2024, King Faisal Specialist Hospital & Research Centre (KFSHRC) launched a virtual pathology service at its Madinah branch that reduces diagnostic turnaround time from over a week to one day, which is anticipated to propel demand for high-quality tissue sections for digital review.

Key Tissue Sectioning Company Insights

The tissue sectioning market is moderately consolidated, with a few global leaders and a large number of specialized and regional suppliers. Leading players include Danaher Corporation (Leica Biosystems), PHC Holdings Corporation (Epredia), Sakura Finetek Japan Co., Ltd., StatLab Medical Products (Diapath S.p.A.), MEDITE Medical GmbH, SLEE medical GmbH, Amos Scientific Pty. Ltd., Bright Instruments Ltd., Boeckeler Instruments, Inc., Precisionary Instruments LLC, Diatome AG, RWD Life Science Co., Ltd., Histo-Line Laboratories S.r.l., Clarapath, Inc., and Charles River Laboratories International, Inc. These companies focus on automated and robotic microtomy, ergonomic and energy-efficient cryostats, premium blades, acquisitions, and expansion of distribution and manufacturing networks.

Key Tissue Sectioning Companies

The following key companies have been profiled for this study on the tissue sectioning market.

• Danaher Corporation (Leica Biosystems)

• PHC Holdings Corporation (Epredia)

• Sakura Finetek Japan Co., Ltd.

• StatLab Medical Products (Diapath S.p.A.)

• MEDITE Medical GmbH

• SLEE medical GmbH

• Amos Scientific Pty. Ltd.

• Bright Instruments Ltd.

• Boeckeler Instruments, Inc.

• Precisionary Instruments LLC

• Diatome AG

• RWD Life Science Co., Ltd.

• Histo-Line Laboratories S.r.l.

• Clarapath, Inc.

• Charles River Laboratories International, Inc.

Recent Developments

• In April 2026, Clarapath released the latest version of its SectionStar platform, an FDA-registered robotic microtomy system for clinical histology laboratories, with enhancements across hardware, software, and user experience. The system was showcased at the USCAP 115th Annual Meeting in March 2026, and installations are underway at qualifying customer sites.

“Automation in histology isn't about replacing expertise-it's about supporting it.”

- Matthew Claster, Chief Business Officer, Clarapath

• In February 2026, Leica Biosystems launched the Leica CM1950 cryostat with DualEcoTec cooling system, which cools specimens up to three times faster, reaches -50 °C, uses a next-generation refrigerant with near-zero global warming potential, and consumes up to 50% less energy than previous models.

“The result is faster turnaround, greater confidence in results, and more efficient workflows.”

- Naveen Chandra, Vice President and General Manager, Digital Pathology & Innovation, Leica Biosystems

• In August 2024, StatLab Medical Products signed a definitive agreement to acquire Diapath, an Italian manufacturer of histology instruments, including microtomes, tissue processors, and embedding centers, to expand its presence in Europe and its instrument portfolio.

“The decision to join StatLab is driven by our shared commitment to growth and innovation to meet customer needs.”

- Vladimiro Bergamini, Founder, Diapath

Global Tissue Sectioning Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global tissue sectioning market on the basis of product, technology, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Instruments

    • Rotary Microtomes

    • Cryostats

    • Ultramicrotomes

    • Vibratomes

    • Others

  • Accessories & Consumables

    • Blades & Knives

    • Cryo-Embedding Media

    • Specimen Holders & Chucks

    • Others

  • Services

• Technology Outlook (Revenue, USD Million, 2021 - 2033)

  • Fully Automated

  • Semi-Automated

  • Manual

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Disease Diagnosis

  • Research

  • Drug Discovery & Preclinical Toxicology

  • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

  • Diagnostic & Pathology Laboratories

  • Academic & Research Institutes

  • Pharmaceutical & Biotechnology Companies and CROs

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait

Research Methodology

The tissue sectioning market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each tissue sectioning segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations